475 related articles for article (PubMed ID: 30699928)
1. Exosomes and the Future of Immunotherapy in Pancreatic Cancer.
Batista IA; Melo SA
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699928
[TBL] [Abstract][Full Text] [Related]
2. Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?
Papadakos SP; Dedes N; Pergaris A; Gazouli M; Theocharis S
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408980
[TBL] [Abstract][Full Text] [Related]
3. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
4. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment.
Zhou W; Zhou Y; Chen X; Ning T; Chen H; Guo Q; Zhang Y; Liu P; Zhang Y; Li C; Chu Y; Sun T; Jiang C
Biomaterials; 2021 Jan; 268():120546. PubMed ID: 33253966
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Sahin IH; Askan G; Hu ZI; O'Reilly EM
Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
[TBL] [Abstract][Full Text] [Related]
7. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
8. Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes.
Massoumi RL; Hines OJ; Eibl G; King JC
Pancreas; 2019 Jan; 48(1):1-8. PubMed ID: 30531240
[TBL] [Abstract][Full Text] [Related]
9. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle.
Kieler M; Unseld M; Bianconi D; Prager G
Pancreas; 2018 Feb; 47(2):142-157. PubMed ID: 29346215
[TBL] [Abstract][Full Text] [Related]
10. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
11. Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis.
Li J; Li Z; Jiang P; Peng M; Zhang X; Chen K; Liu H; Bi H; Liu X; Li X
J Exp Clin Cancer Res; 2018 Jul; 37(1):177. PubMed ID: 30064461
[TBL] [Abstract][Full Text] [Related]
12. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
Ye C; Zheng L; Yuan CH
Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
[TBL] [Abstract][Full Text] [Related]
13. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
Tan E; El-Rayes B
J Gastrointest Cancer; 2019 Mar; 50(1):1-8. PubMed ID: 30446922
[TBL] [Abstract][Full Text] [Related]
16. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
17. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions.
Bandi DSR; Sarvesh S; Farran B; Nagaraju GP; El-Rayes BF
Cytokine Growth Factor Rev; 2023; 71-72():26-39. PubMed ID: 37407355
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for pancreatic ductal adenocarcinoma.
Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
[TBL] [Abstract][Full Text] [Related]
19. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.
Gomez-Chou SB; Swidnicka-Siergiejko AK; Badi N; Chavez-Tomar M; Lesinski GB; Bekaii-Saab T; Farren MR; Mace TA; Schmidt C; Liu Y; Deng D; Hwang RF; Zhou L; Moore T; Chatterjee D; Wang H; Leng X; Arlinghaus RB; Logsdon CD; Cruz-Monserrate Z
Cancer Res; 2017 May; 77(10):2647-2660. PubMed ID: 28249896
[TBL] [Abstract][Full Text] [Related]
20. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]